title: Intracranial hemangiopericytoma and the role of radiation therapy:  a population based analysis.
abstract: BACKGROUND
  Intracranial hemangiopericytoma (HPC) is a rare malignancy for which treatment recommendations vary.
  
  
  OBJECTIVE
  We sought to characterize outcomes of HPC patients treated with postoperative external beam radiotherapy (PORT).
  
  
  METHODS
  A retrospective analysis was conducted using the Surveillance, Epidemiology and End Results (SEER) Program of the US National Cancer Institute. We identified patients with intracranial hemangiopericytoma who underwent surgery alone or PORT.
  
  
  RESULTS
  We identified 88 patients with a diagnosis of HPC between 1982 and 2009 treated with surgery alone or PORT. The majority of patients were female (53%) and white (84%) with a median age of 50.5 years (range, 0-92 years). Gross total resection (GTR) was achieved in 55%, and PORT was delivered to 48% of the entire cohort. The median overall survival (OS) and cause-specific survival (CSS) were 111 months and 161 months, respectively. On univariate analysis, age older than 50 years correlated with poor OS (hazard ratio [HR]: 3.43; 95% confidence interval [CI]: 1.70-6.95; P = .001) and CSS (HR: 2.77; 95% CI: 1.18-6.48; P = .019). On multivariate analysis (MVA), age >50 years correlated with poor OS (HR: 3.69; 95% CI: 1.72-7.93; P = .001) and CSS (HR: 2.67; 95% CI: 1.08-6.59; P = .034). On MVA, GTR correlated with improved OS (HR: 0.28; 95% CI: 0.11-0.71; P = .007) and CSS (HR: 0.23; 95% CI: 0.07-0.76; P = .016). In addition, PORT correlated with improved OS (MVA HR: 0.02; 95% CI: 0.00-0.31; P = .005) and CSS (MVA HR: 0.02; 95% CI: 0.00-0.45; P = .015). Patients undergoing STR with PORT compared favorably with those undergoing GTR alone with respect to OS (HR: 0.43; 95% CI: 0.15-1.26; P = .13) and CSS (HR: 0.51; 95% CI: 0.15-1.78; P = .29).
  
  
  CONCLUSIONS
  In intracranial HPC, both PORT and GTR independently correlate with improved OS and CSS.
authors.affiliation: Department of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA. ajghia@mdanderson.org
authors.forename: Amol J
authors.initials: AJ
authors.lastname: Ghia
authors.forename: Pamela K
authors.initials: PK
authors.lastname: Allen
authors.forename: Anita
authors.initials: A
authors.lastname: Mahajan
authors.forename: Marta
authors.initials: M
authors.lastname: Penas-Prado
authors.forename: Ian E
authors.initials: IE
authors.lastname: McCutcheon
authors.forename: Paul D
authors.initials: PD
authors.lastname: Brown
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001932:Brain Neoplasms / Q000453:epidemiology* / Q000532:radiotherapy* / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D018672:Community Health Planning; D005260:Female; D006393:Hemangiopericytoma / Q000453:epidemiology* / Q000532:radiotherapy* / Q000601:surgery; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D054547:National Cancer Institute (U.S.); D061766:Proton Therapy / Q000379:methods*; D012189:Retrospective Studies; D016019:Survival Analysis; D015996:Survival Rate; D016896:Treatment Outcome; D014481:United States; D055815:Young Adult